{"id":59954,"date":"2024-02-28T06:25:37","date_gmt":"2024-02-28T06:25:37","guid":{"rendered":"https:\/\/medsname.com\/palip-xr\/"},"modified":"2026-04-30T10:23:52","modified_gmt":"2026-04-30T10:23:52","slug":"palip-xr","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/palip-xr\/","title":{"rendered":"Palip XR"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Hurtigt svar<\/h3>\n

Palip XR (Paliperidone 3 \/ 6 \/ 9 mg XR, extended-release) is an atypical antipsychotic for schizophrenia and schizoaffective disorder. Active metabolite of risperidone, dosed once daily via OROS osmotic-pump tablet. Largely renally cleared \u2014 dose-adjust in renal impairment.<\/p>\n<\/div>\n

\nHvad du f\u00e5r med MedsBase:<\/strong> WHO-GMP certificeret producent \u00b7 Diskret emballage \u00b7 Verdensomsp\u00e6ndende forsendelse \u00b7 1.400+ verificerede kundeanmeldelser<\/a>\n<\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n

Hvorfor bestille fra MedsBase<\/h3>\n

Palip XR at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Reshipment Assurance Policy<\/a> \u2014 20-hverdages leveringsvindue eller vi gensender uden ekstra omkostninger \u2014 og kvalificerer sig til vores kundeloyalitetsprogram<\/a>. Verdensomsp\u00e6ndende forsendelse er tilg\u00e6ngelig til de fleste destinationer.<\/p>\n

What Palip XR is and how it works<\/h2>\n

Palip XR is a paliperidone extended-release tablet supplied by Sun Pharma. Available strengths: 3 \/ 6 \/ 9 mg XR<\/strong>. Paliperidone is the major active metabolite of risperidone (9-hydroxyrisperidone). Pharmacologically very similar \u2014 strong D2 and 5-HT2A antagonism, prolactin elevation, EPS at higher doses \u2014 but with two practical differences: (1) the OROS extended-release formulation produces a flat 24-hour plasma curve (smoother tolerability than risperidone IR), and (2) paliperidone is largely renally cleared (75%) rather than hepatically metabolised, so it is unaffected by CYP-altering drugs but requires dose adjustment in renal impairment.<\/p>\n

Indikationer og dosering<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikation<\/th>\nStartdosis<\/th>\nM\u00e5ldosis<\/th>\nMaksimal dosis<\/th>\n<\/tr>\n<\/thead>\n
Skizofreni (voksen)<\/td>\n6 mg OD morning<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Schizophrenia (adolescent \u2265 12 y, \u2265 51 kg)<\/td>\n3 mg OD<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Schizoaffective disorder<\/td>\n6 mg OD<\/td>\n3\u201312 mg OD<\/td>\n12 mg<\/td>\n<\/tr>\n
Renal impairment (CrCl 50\u201380)<\/td>\n3 mg OD<\/td>\nup to 6 mg<\/td>\n6 mg<\/td>\n<\/tr>\n
Renal impairment (CrCl 10\u201350)<\/td>\n1.5 mg OD<\/td>\nup to 3 mg<\/td>\n3 mg<\/td>\n<\/tr>\n
Nedsat nyrefunktion (CrCl < 10)<\/td>\nikke anbefalet<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Take whole \u2014 do not crush, chew, or split. The OROS osmotic pump shell will pass intact in stool \u2014 this is normal and expected.<\/p>\n

Vigtige sikkerhedsovervejelser<\/h2>\n
\nFDA black-box \u2014 demensrelateret psykose<\/strong><\/p>\n

Alle atypiske antipsykotika b\u00e6rer en FDA black-box advarsel om \u00f8get d\u00f8delighed (prim\u00e6rt kardiovaskul\u00e6r og infektionsrelateret) ved brug til behandling af adf\u00e6rdsforstyrrelser hos \u00e6ldre med demens. Atypiske antipsykotika er ikke godkendt til demensrelateret psykose eller agitation.<\/strong>. Brug i denne population er off-label, sidste udvej, tidsbegr\u00e6nset og kr\u00e6ver en eksplicit risici-fordel samtale.<\/p>\n<\/div>\n

\nHyperprolactinaemia (similar to risperidone)<\/strong><\/p>\n

As an active risperidone metabolite, paliperidone produces the same prolactin elevation: amenorrhoea, galactorrhoea, sexual dysfunction, and long-term bone-density loss. Monitor as for risperidone; switch to a prolactin-sparing atypical (aripiprazole, quetiapine) if symptomatic.<\/p>\n<\/div>\n

\nEPS \/ dose-dependent<\/strong><\/p>\n

Above 6 mg\/day, EPS and akathisia rise in frequency. Dose-dependent.<\/p>\n<\/div>\n

\nGI obstruction caveat<\/strong><\/p>\n

The non-deformable OROS tablet is theoretically problematic in pre-existing severe GI narrowing (severe Crohn’s strictures, oesophageal stricture, prior bowel resection). Rare clinically, but worth noting.<\/p>\n<\/div>\n

Almindelige bivirkninger<\/h2>\n